nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—ABCB1—kidney cancer	0.165	1	CbGaD
Citalopram—ABCB1—Temsirolimus—kidney cancer	0.0356	0.0731	CbGbCtD
Citalopram—HTR2C—Sorafenib—kidney cancer	0.0341	0.0701	CbGbCtD
Citalopram—CYP2D6—Temsirolimus—kidney cancer	0.0335	0.0689	CbGbCtD
Citalopram—CYP3A4—Everolimus—kidney cancer	0.0315	0.0649	CbGbCtD
Citalopram—CYP1A2—Pazopanib—kidney cancer	0.0214	0.0439	CbGbCtD
Citalopram—CYP3A4—Temsirolimus—kidney cancer	0.0213	0.0438	CbGbCtD
Citalopram—CYP2B6—Sorafenib—kidney cancer	0.0211	0.0435	CbGbCtD
Citalopram—ABCB1—Pazopanib—kidney cancer	0.0187	0.0384	CbGbCtD
Citalopram—CYP2D6—Pazopanib—kidney cancer	0.0176	0.0362	CbGbCtD
Citalopram—ABCB1—Dactinomycin—kidney cancer	0.0171	0.0351	CbGbCtD
Citalopram—CYP1A2—Erlotinib—kidney cancer	0.0152	0.0314	CbGbCtD
Citalopram—ABCB1—Gemcitabine—kidney cancer	0.0135	0.0278	CbGbCtD
Citalopram—CYP2C19—Sorafenib—kidney cancer	0.0134	0.0276	CbGbCtD
Citalopram—ABCB1—Erlotinib—kidney cancer	0.0133	0.0274	CbGbCtD
Citalopram—CYP2B6—Doxorubicin—kidney cancer	0.0128	0.0264	CbGbCtD
Citalopram—CYP2D6—Erlotinib—kidney cancer	0.0126	0.0258	CbGbCtD
Citalopram—CYP1A2—Sorafenib—kidney cancer	0.0124	0.0255	CbGbCtD
Citalopram—ABCB1—Paclitaxel—kidney cancer	0.0122	0.0251	CbGbCtD
Citalopram—CYP3A4—Pazopanib—kidney cancer	0.0112	0.023	CbGbCtD
Citalopram—ABCB1—Sorafenib—kidney cancer	0.0108	0.0223	CbGbCtD
Citalopram—ABCB1—Vinblastine—kidney cancer	0.0107	0.022	CbGbCtD
Citalopram—ABCB1—Vincristine—kidney cancer	0.0105	0.0216	CbGbCtD
Citalopram—CYP2D6—Sorafenib—kidney cancer	0.0102	0.021	CbGbCtD
Citalopram—CYP2D6—Vinblastine—kidney cancer	0.0101	0.0207	CbGbCtD
Citalopram—ABCB1—Sunitinib—kidney cancer	0.00878	0.0181	CbGbCtD
Citalopram—CYP3A4—Erlotinib—kidney cancer	0.00799	0.0164	CbGbCtD
Citalopram—CYP3A4—Paclitaxel—kidney cancer	0.00731	0.015	CbGbCtD
Citalopram—ABCB1—Doxorubicin—kidney cancer	0.00658	0.0135	CbGbCtD
Citalopram—CYP3A4—Sorafenib—kidney cancer	0.00649	0.0134	CbGbCtD
Citalopram—CYP3A4—Vinblastine—kidney cancer	0.00641	0.0132	CbGbCtD
Citalopram—CYP3A4—Vincristine—kidney cancer	0.0063	0.013	CbGbCtD
Citalopram—CYP2D6—Doxorubicin—kidney cancer	0.0062	0.0127	CbGbCtD
Citalopram—CYP3A4—Sunitinib—kidney cancer	0.00526	0.0108	CbGbCtD
Citalopram—CYP3A4—Doxorubicin—kidney cancer	0.00394	0.0081	CbGbCtD
Citalopram—CYP2C19—urine—kidney cancer	0.00136	0.144	CbGeAlD
Citalopram—CYP1A2—urine—kidney cancer	0.00111	0.118	CbGeAlD
Citalopram—CYP2E1—urine—kidney cancer	0.000997	0.106	CbGeAlD
Citalopram—CYP3A4—urine—kidney cancer	0.000803	0.0851	CbGeAlD
Citalopram—CYP2D6—urine—kidney cancer	0.00079	0.0838	CbGeAlD
Citalopram—ADRA1A—renal system—kidney cancer	0.000328	0.0348	CbGeAlD
Citalopram—SLC6A2—gonad—kidney cancer	0.000316	0.0336	CbGeAlD
Citalopram—CYP2B6—nephron tubule—kidney cancer	0.000286	0.0303	CbGeAlD
Citalopram—CYP1A2—renal system—kidney cancer	0.000271	0.0288	CbGeAlD
Citalopram—CYP2E1—nephron tubule—kidney cancer	0.000268	0.0285	CbGeAlD
Citalopram—CYP2B6—renal system—kidney cancer	0.00026	0.0276	CbGeAlD
Citalopram—CYP2B6—kidney—kidney cancer	0.000251	0.0267	CbGeAlD
Citalopram—CYP2E1—renal system—kidney cancer	0.000244	0.0259	CbGeAlD
Citalopram—CYP2E1—kidney—kidney cancer	0.000236	0.025	CbGeAlD
Citalopram—CYP2B6—gonad—kidney cancer	0.000233	0.0247	CbGeAlD
Citalopram—CYP2E1—cortex of kidney—kidney cancer	0.00023	0.0244	CbGeAlD
Citalopram—CYP3A4—renal system—kidney cancer	0.000196	0.0208	CbGeAlD
Citalopram—CYP2D6—renal system—kidney cancer	0.000193	0.0205	CbGeAlD
Citalopram—CYP3A4—kidney—kidney cancer	0.00019	0.0201	CbGeAlD
Citalopram—CYP2D6—kidney—kidney cancer	0.000187	0.0198	CbGeAlD
Citalopram—ABCB1—nephron tubule—kidney cancer	0.000153	0.0162	CbGeAlD
Citalopram—ABCB1—renal system—kidney cancer	0.000139	0.0147	CbGeAlD
Citalopram—ABCB1—kidney—kidney cancer	0.000134	0.0143	CbGeAlD
Citalopram—ABCB1—cortex of kidney—kidney cancer	0.000131	0.0139	CbGeAlD
Citalopram—ABCB1—gonad—kidney cancer	0.000125	0.0132	CbGeAlD
Citalopram—Nervous system disorder—Paclitaxel—kidney cancer	4.36e-05	0.000149	CcSEcCtD
Citalopram—Hypokalaemia—Doxorubicin—kidney cancer	4.36e-05	0.000148	CcSEcCtD
Citalopram—Thrombocytopenia—Paclitaxel—kidney cancer	4.35e-05	0.000148	CcSEcCtD
Citalopram—Tachycardia—Paclitaxel—kidney cancer	4.34e-05	0.000148	CcSEcCtD
Citalopram—Rash—Sorafenib—kidney cancer	4.34e-05	0.000148	CcSEcCtD
Citalopram—Dermatitis—Sorafenib—kidney cancer	4.33e-05	0.000148	CcSEcCtD
Citalopram—Back pain—Capecitabine—kidney cancer	4.33e-05	0.000147	CcSEcCtD
Citalopram—Breast disorder—Doxorubicin—kidney cancer	4.32e-05	0.000147	CcSEcCtD
Citalopram—Skin disorder—Paclitaxel—kidney cancer	4.32e-05	0.000147	CcSEcCtD
Citalopram—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	4.31e-05	0.000147	CcSEcCtD
Citalopram—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	4.31e-05	0.000147	CcSEcCtD
Citalopram—Headache—Sorafenib—kidney cancer	4.31e-05	0.000147	CcSEcCtD
Citalopram—Muscle spasms—Capecitabine—kidney cancer	4.3e-05	0.000146	CcSEcCtD
Citalopram—Hyperhidrosis—Paclitaxel—kidney cancer	4.3e-05	0.000146	CcSEcCtD
Citalopram—Diarrhoea—Dactinomycin—kidney cancer	4.29e-05	0.000146	CcSEcCtD
Citalopram—Nasopharyngitis—Doxorubicin—kidney cancer	4.28e-05	0.000146	CcSEcCtD
Citalopram—Anorexia—Paclitaxel—kidney cancer	4.24e-05	0.000144	CcSEcCtD
Citalopram—Gastritis—Doxorubicin—kidney cancer	4.24e-05	0.000144	CcSEcCtD
Citalopram—Alanine aminotransferase increased—Doxorubicin—kidney cancer	4.22e-05	0.000144	CcSEcCtD
Citalopram—Muscular weakness—Doxorubicin—kidney cancer	4.22e-05	0.000144	CcSEcCtD
Citalopram—Vision blurred—Capecitabine—kidney cancer	4.21e-05	0.000144	CcSEcCtD
Citalopram—Vomiting—Sunitinib—kidney cancer	4.21e-05	0.000143	CcSEcCtD
Citalopram—Body temperature increased—Gemcitabine—kidney cancer	4.2e-05	0.000143	CcSEcCtD
Citalopram—Tremor—Capecitabine—kidney cancer	4.19e-05	0.000143	CcSEcCtD
Citalopram—Rash—Sunitinib—kidney cancer	4.17e-05	0.000142	CcSEcCtD
Citalopram—Dermatitis—Sunitinib—kidney cancer	4.17e-05	0.000142	CcSEcCtD
Citalopram—Abdominal distension—Doxorubicin—kidney cancer	4.16e-05	0.000142	CcSEcCtD
Citalopram—Hypotension—Paclitaxel—kidney cancer	4.16e-05	0.000142	CcSEcCtD
Citalopram—Ill-defined disorder—Capecitabine—kidney cancer	4.15e-05	0.000141	CcSEcCtD
Citalopram—Headache—Sunitinib—kidney cancer	4.15e-05	0.000141	CcSEcCtD
Citalopram—Dysphagia—Doxorubicin—kidney cancer	4.14e-05	0.000141	CcSEcCtD
Citalopram—Influenza—Doxorubicin—kidney cancer	4.14e-05	0.000141	CcSEcCtD
Citalopram—Asthma—Doxorubicin—kidney cancer	4.14e-05	0.000141	CcSEcCtD
Citalopram—Anaemia—Capecitabine—kidney cancer	4.13e-05	0.000141	CcSEcCtD
Citalopram—Hypersensitivity—Vincristine—kidney cancer	4.12e-05	0.00014	CcSEcCtD
Citalopram—Eosinophilia—Doxorubicin—kidney cancer	4.1e-05	0.000139	CcSEcCtD
Citalopram—Nausea—Sorafenib—kidney cancer	4.09e-05	0.000139	CcSEcCtD
Citalopram—Pancreatitis—Doxorubicin—kidney cancer	4.06e-05	0.000138	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Paclitaxel—kidney cancer	4.05e-05	0.000138	CcSEcCtD
Citalopram—Malaise—Capecitabine—kidney cancer	4.03e-05	0.000137	CcSEcCtD
Citalopram—Angina pectoris—Doxorubicin—kidney cancer	4.03e-05	0.000137	CcSEcCtD
Citalopram—Insomnia—Paclitaxel—kidney cancer	4.02e-05	0.000137	CcSEcCtD
Citalopram—Vertigo—Capecitabine—kidney cancer	4.02e-05	0.000137	CcSEcCtD
Citalopram—Asthenia—Vincristine—kidney cancer	4.02e-05	0.000137	CcSEcCtD
Citalopram—Syncope—Capecitabine—kidney cancer	4.01e-05	0.000137	CcSEcCtD
Citalopram—Leukopenia—Capecitabine—kidney cancer	4e-05	0.000136	CcSEcCtD
Citalopram—Paraesthesia—Paclitaxel—kidney cancer	3.99e-05	0.000136	CcSEcCtD
Citalopram—Vomiting—Dactinomycin—kidney cancer	3.98e-05	0.000136	CcSEcCtD
Citalopram—Bronchitis—Doxorubicin—kidney cancer	3.98e-05	0.000135	CcSEcCtD
Citalopram—Dyspnoea—Paclitaxel—kidney cancer	3.96e-05	0.000135	CcSEcCtD
Citalopram—Somnolence—Paclitaxel—kidney cancer	3.95e-05	0.000135	CcSEcCtD
Citalopram—Palpitations—Capecitabine—kidney cancer	3.95e-05	0.000135	CcSEcCtD
Citalopram—Rash—Dactinomycin—kidney cancer	3.95e-05	0.000135	CcSEcCtD
Citalopram—Nausea—Sunitinib—kidney cancer	3.93e-05	0.000134	CcSEcCtD
Citalopram—Loss of consciousness—Capecitabine—kidney cancer	3.93e-05	0.000134	CcSEcCtD
Citalopram—Pancytopenia—Doxorubicin—kidney cancer	3.93e-05	0.000134	CcSEcCtD
Citalopram—Dyspepsia—Paclitaxel—kidney cancer	3.91e-05	0.000133	CcSEcCtD
Citalopram—Cough—Capecitabine—kidney cancer	3.9e-05	0.000133	CcSEcCtD
Citalopram—Dysuria—Doxorubicin—kidney cancer	3.87e-05	0.000132	CcSEcCtD
Citalopram—Decreased appetite—Paclitaxel—kidney cancer	3.87e-05	0.000132	CcSEcCtD
Citalopram—Hypertension—Capecitabine—kidney cancer	3.86e-05	0.000131	CcSEcCtD
Citalopram—Upper respiratory tract infection—Doxorubicin—kidney cancer	3.84e-05	0.000131	CcSEcCtD
Citalopram—Gastrointestinal disorder—Paclitaxel—kidney cancer	3.84e-05	0.000131	CcSEcCtD
Citalopram—Fatigue—Paclitaxel—kidney cancer	3.83e-05	0.000131	CcSEcCtD
Citalopram—Diarrhoea—Vincristine—kidney cancer	3.83e-05	0.00013	CcSEcCtD
Citalopram—Pollakiuria—Doxorubicin—kidney cancer	3.82e-05	0.00013	CcSEcCtD
Citalopram—Asthenia—Gemcitabine—kidney cancer	3.81e-05	0.00013	CcSEcCtD
Citalopram—Chest pain—Capecitabine—kidney cancer	3.81e-05	0.00013	CcSEcCtD
Citalopram—Myalgia—Capecitabine—kidney cancer	3.81e-05	0.00013	CcSEcCtD
Citalopram—Arthralgia—Capecitabine—kidney cancer	3.81e-05	0.00013	CcSEcCtD
Citalopram—Pain—Paclitaxel—kidney cancer	3.8e-05	0.00013	CcSEcCtD
Citalopram—Constipation—Paclitaxel—kidney cancer	3.8e-05	0.00013	CcSEcCtD
Citalopram—Anxiety—Capecitabine—kidney cancer	3.79e-05	0.000129	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	3.78e-05	0.000129	CcSEcCtD
Citalopram—Photosensitivity reaction—Doxorubicin—kidney cancer	3.78e-05	0.000129	CcSEcCtD
Citalopram—Weight increased—Doxorubicin—kidney cancer	3.76e-05	0.000128	CcSEcCtD
Citalopram—Discomfort—Capecitabine—kidney cancer	3.76e-05	0.000128	CcSEcCtD
Citalopram—Pruritus—Gemcitabine—kidney cancer	3.76e-05	0.000128	CcSEcCtD
Citalopram—Weight decreased—Doxorubicin—kidney cancer	3.74e-05	0.000127	CcSEcCtD
Citalopram—Hyperglycaemia—Doxorubicin—kidney cancer	3.73e-05	0.000127	CcSEcCtD
Citalopram—Dry mouth—Capecitabine—kidney cancer	3.72e-05	0.000127	CcSEcCtD
Citalopram—Nausea—Dactinomycin—kidney cancer	3.72e-05	0.000127	CcSEcCtD
Citalopram—Pneumonia—Doxorubicin—kidney cancer	3.71e-05	0.000126	CcSEcCtD
Citalopram—Dizziness—Vincristine—kidney cancer	3.7e-05	0.000126	CcSEcCtD
Citalopram—Infestation NOS—Doxorubicin—kidney cancer	3.69e-05	0.000126	CcSEcCtD
Citalopram—Infestation—Doxorubicin—kidney cancer	3.69e-05	0.000126	CcSEcCtD
Citalopram—Confusional state—Capecitabine—kidney cancer	3.68e-05	0.000125	CcSEcCtD
Citalopram—Feeling abnormal—Paclitaxel—kidney cancer	3.66e-05	0.000125	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	3.66e-05	0.000125	CcSEcCtD
Citalopram—Oedema—Capecitabine—kidney cancer	3.65e-05	0.000124	CcSEcCtD
Citalopram—Gastrointestinal pain—Paclitaxel—kidney cancer	3.64e-05	0.000124	CcSEcCtD
Citalopram—Diarrhoea—Gemcitabine—kidney cancer	3.63e-05	0.000124	CcSEcCtD
Citalopram—Infection—Capecitabine—kidney cancer	3.63e-05	0.000123	CcSEcCtD
Citalopram—Neuropathy peripheral—Doxorubicin—kidney cancer	3.62e-05	0.000123	CcSEcCtD
Citalopram—Stomatitis—Doxorubicin—kidney cancer	3.6e-05	0.000122	CcSEcCtD
Citalopram—Jaundice—Doxorubicin—kidney cancer	3.6e-05	0.000122	CcSEcCtD
Citalopram—Shock—Capecitabine—kidney cancer	3.59e-05	0.000122	CcSEcCtD
Citalopram—Conjunctivitis—Doxorubicin—kidney cancer	3.59e-05	0.000122	CcSEcCtD
Citalopram—Urinary tract infection—Doxorubicin—kidney cancer	3.59e-05	0.000122	CcSEcCtD
Citalopram—Nervous system disorder—Capecitabine—kidney cancer	3.58e-05	0.000122	CcSEcCtD
Citalopram—Thrombocytopenia—Capecitabine—kidney cancer	3.57e-05	0.000122	CcSEcCtD
Citalopram—Tachycardia—Capecitabine—kidney cancer	3.56e-05	0.000121	CcSEcCtD
Citalopram—Vomiting—Vincristine—kidney cancer	3.56e-05	0.000121	CcSEcCtD
Citalopram—Skin disorder—Capecitabine—kidney cancer	3.54e-05	0.000121	CcSEcCtD
Citalopram—Sweating—Doxorubicin—kidney cancer	3.54e-05	0.00012	CcSEcCtD
Citalopram—Urticaria—Paclitaxel—kidney cancer	3.53e-05	0.00012	CcSEcCtD
Citalopram—Rash—Vincristine—kidney cancer	3.53e-05	0.00012	CcSEcCtD
Citalopram—Hyperhidrosis—Capecitabine—kidney cancer	3.53e-05	0.00012	CcSEcCtD
Citalopram—Dermatitis—Vincristine—kidney cancer	3.53e-05	0.00012	CcSEcCtD
Citalopram—Haematuria—Doxorubicin—kidney cancer	3.52e-05	0.00012	CcSEcCtD
Citalopram—Abdominal pain—Paclitaxel—kidney cancer	3.52e-05	0.00012	CcSEcCtD
Citalopram—Body temperature increased—Paclitaxel—kidney cancer	3.52e-05	0.00012	CcSEcCtD
Citalopram—Headache—Vincristine—kidney cancer	3.51e-05	0.000119	CcSEcCtD
Citalopram—Hepatobiliary disease—Doxorubicin—kidney cancer	3.49e-05	0.000119	CcSEcCtD
Citalopram—Epistaxis—Doxorubicin—kidney cancer	3.48e-05	0.000118	CcSEcCtD
Citalopram—Anorexia—Capecitabine—kidney cancer	3.48e-05	0.000118	CcSEcCtD
Citalopram—Sinusitis—Doxorubicin—kidney cancer	3.46e-05	0.000118	CcSEcCtD
Citalopram—Agranulocytosis—Doxorubicin—kidney cancer	3.44e-05	0.000117	CcSEcCtD
Citalopram—Hypotension—Capecitabine—kidney cancer	3.41e-05	0.000116	CcSEcCtD
Citalopram—Vomiting—Gemcitabine—kidney cancer	3.38e-05	0.000115	CcSEcCtD
Citalopram—Bradycardia—Doxorubicin—kidney cancer	3.37e-05	0.000115	CcSEcCtD
Citalopram—Rash—Gemcitabine—kidney cancer	3.35e-05	0.000114	CcSEcCtD
Citalopram—Dermatitis—Gemcitabine—kidney cancer	3.35e-05	0.000114	CcSEcCtD
Citalopram—Haemoglobin—Doxorubicin—kidney cancer	3.33e-05	0.000113	CcSEcCtD
Citalopram—Headache—Gemcitabine—kidney cancer	3.33e-05	0.000113	CcSEcCtD
Citalopram—Nausea—Vincristine—kidney cancer	3.33e-05	0.000113	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Capecitabine—kidney cancer	3.32e-05	0.000113	CcSEcCtD
Citalopram—Rhinitis—Doxorubicin—kidney cancer	3.32e-05	0.000113	CcSEcCtD
Citalopram—Haemorrhage—Doxorubicin—kidney cancer	3.31e-05	0.000113	CcSEcCtD
Citalopram—Hepatitis—Doxorubicin—kidney cancer	3.31e-05	0.000113	CcSEcCtD
Citalopram—Insomnia—Capecitabine—kidney cancer	3.3e-05	0.000112	CcSEcCtD
Citalopram—Hypoaesthesia—Doxorubicin—kidney cancer	3.29e-05	0.000112	CcSEcCtD
Citalopram—Pharyngitis—Doxorubicin—kidney cancer	3.29e-05	0.000112	CcSEcCtD
Citalopram—Paraesthesia—Capecitabine—kidney cancer	3.28e-05	0.000112	CcSEcCtD
Citalopram—Hypersensitivity—Paclitaxel—kidney cancer	3.28e-05	0.000112	CcSEcCtD
Citalopram—Urinary tract disorder—Doxorubicin—kidney cancer	3.27e-05	0.000111	CcSEcCtD
Citalopram—Oedema peripheral—Doxorubicin—kidney cancer	3.26e-05	0.000111	CcSEcCtD
Citalopram—Connective tissue disorder—Doxorubicin—kidney cancer	3.25e-05	0.000111	CcSEcCtD
Citalopram—Dyspnoea—Capecitabine—kidney cancer	3.25e-05	0.000111	CcSEcCtD
Citalopram—Urethral disorder—Doxorubicin—kidney cancer	3.25e-05	0.000111	CcSEcCtD
Citalopram—Dyspepsia—Capecitabine—kidney cancer	3.21e-05	0.000109	CcSEcCtD
Citalopram—Visual impairment—Doxorubicin—kidney cancer	3.19e-05	0.000109	CcSEcCtD
Citalopram—Asthenia—Paclitaxel—kidney cancer	3.19e-05	0.000109	CcSEcCtD
Citalopram—Decreased appetite—Capecitabine—kidney cancer	3.17e-05	0.000108	CcSEcCtD
Citalopram—Nausea—Gemcitabine—kidney cancer	3.15e-05	0.000107	CcSEcCtD
Citalopram—Gastrointestinal disorder—Capecitabine—kidney cancer	3.15e-05	0.000107	CcSEcCtD
Citalopram—Fatigue—Capecitabine—kidney cancer	3.15e-05	0.000107	CcSEcCtD
Citalopram—Pruritus—Paclitaxel—kidney cancer	3.15e-05	0.000107	CcSEcCtD
Citalopram—Erythema multiforme—Doxorubicin—kidney cancer	3.13e-05	0.000107	CcSEcCtD
Citalopram—Pain—Capecitabine—kidney cancer	3.12e-05	0.000106	CcSEcCtD
Citalopram—Constipation—Capecitabine—kidney cancer	3.12e-05	0.000106	CcSEcCtD
Citalopram—Eye disorder—Doxorubicin—kidney cancer	3.09e-05	0.000105	CcSEcCtD
Citalopram—Tinnitus—Doxorubicin—kidney cancer	3.09e-05	0.000105	CcSEcCtD
Citalopram—Flushing—Doxorubicin—kidney cancer	3.07e-05	0.000105	CcSEcCtD
Citalopram—Cardiac disorder—Doxorubicin—kidney cancer	3.07e-05	0.000105	CcSEcCtD
Citalopram—Diarrhoea—Paclitaxel—kidney cancer	3.04e-05	0.000104	CcSEcCtD
Citalopram—Feeling abnormal—Capecitabine—kidney cancer	3.01e-05	0.000102	CcSEcCtD
Citalopram—Angiopathy—Doxorubicin—kidney cancer	3e-05	0.000102	CcSEcCtD
Citalopram—Immune system disorder—Doxorubicin—kidney cancer	2.99e-05	0.000102	CcSEcCtD
Citalopram—Gastrointestinal pain—Capecitabine—kidney cancer	2.98e-05	0.000102	CcSEcCtD
Citalopram—Mediastinal disorder—Doxorubicin—kidney cancer	2.98e-05	0.000102	CcSEcCtD
Citalopram—Chills—Doxorubicin—kidney cancer	2.97e-05	0.000101	CcSEcCtD
Citalopram—Arrhythmia—Doxorubicin—kidney cancer	2.96e-05	0.000101	CcSEcCtD
Citalopram—Dizziness—Paclitaxel—kidney cancer	2.94e-05	0.0001	CcSEcCtD
Citalopram—Alopecia—Doxorubicin—kidney cancer	2.93e-05	9.97e-05	CcSEcCtD
Citalopram—Mental disorder—Doxorubicin—kidney cancer	2.9e-05	9.88e-05	CcSEcCtD
Citalopram—Urticaria—Capecitabine—kidney cancer	2.9e-05	9.87e-05	CcSEcCtD
Citalopram—Body temperature increased—Capecitabine—kidney cancer	2.88e-05	9.83e-05	CcSEcCtD
Citalopram—Abdominal pain—Capecitabine—kidney cancer	2.88e-05	9.83e-05	CcSEcCtD
Citalopram—Erythema—Doxorubicin—kidney cancer	2.88e-05	9.82e-05	CcSEcCtD
Citalopram—Malnutrition—Doxorubicin—kidney cancer	2.88e-05	9.82e-05	CcSEcCtD
Citalopram—Flatulence—Doxorubicin—kidney cancer	2.84e-05	9.67e-05	CcSEcCtD
Citalopram—Tension—Doxorubicin—kidney cancer	2.83e-05	9.63e-05	CcSEcCtD
Citalopram—Vomiting—Paclitaxel—kidney cancer	2.83e-05	9.63e-05	CcSEcCtD
Citalopram—Dysgeusia—Doxorubicin—kidney cancer	2.82e-05	9.61e-05	CcSEcCtD
Citalopram—Rash—Paclitaxel—kidney cancer	2.8e-05	9.55e-05	CcSEcCtD
Citalopram—Dermatitis—Paclitaxel—kidney cancer	2.8e-05	9.54e-05	CcSEcCtD
Citalopram—Nervousness—Doxorubicin—kidney cancer	2.8e-05	9.53e-05	CcSEcCtD
Citalopram—Back pain—Doxorubicin—kidney cancer	2.79e-05	9.5e-05	CcSEcCtD
Citalopram—Headache—Paclitaxel—kidney cancer	2.79e-05	9.49e-05	CcSEcCtD
Citalopram—Muscle spasms—Doxorubicin—kidney cancer	2.77e-05	9.44e-05	CcSEcCtD
Citalopram—Vision blurred—Doxorubicin—kidney cancer	2.72e-05	9.25e-05	CcSEcCtD
Citalopram—Hypersensitivity—Capecitabine—kidney cancer	2.69e-05	9.16e-05	CcSEcCtD
Citalopram—Ill-defined disorder—Doxorubicin—kidney cancer	2.67e-05	9.11e-05	CcSEcCtD
Citalopram—Anaemia—Doxorubicin—kidney cancer	2.66e-05	9.07e-05	CcSEcCtD
Citalopram—Agitation—Doxorubicin—kidney cancer	2.65e-05	9.02e-05	CcSEcCtD
Citalopram—Nausea—Paclitaxel—kidney cancer	2.64e-05	9e-05	CcSEcCtD
Citalopram—Asthenia—Capecitabine—kidney cancer	2.62e-05	8.92e-05	CcSEcCtD
Citalopram—Malaise—Doxorubicin—kidney cancer	2.6e-05	8.85e-05	CcSEcCtD
Citalopram—Vertigo—Doxorubicin—kidney cancer	2.59e-05	8.82e-05	CcSEcCtD
Citalopram—Syncope—Doxorubicin—kidney cancer	2.58e-05	8.8e-05	CcSEcCtD
Citalopram—Pruritus—Capecitabine—kidney cancer	2.58e-05	8.79e-05	CcSEcCtD
Citalopram—Leukopenia—Doxorubicin—kidney cancer	2.58e-05	8.79e-05	CcSEcCtD
Citalopram—Palpitations—Doxorubicin—kidney cancer	2.55e-05	8.68e-05	CcSEcCtD
Citalopram—Loss of consciousness—Doxorubicin—kidney cancer	2.53e-05	8.63e-05	CcSEcCtD
Citalopram—Cough—Doxorubicin—kidney cancer	2.52e-05	8.57e-05	CcSEcCtD
Citalopram—Convulsion—Doxorubicin—kidney cancer	2.5e-05	8.51e-05	CcSEcCtD
Citalopram—Diarrhoea—Capecitabine—kidney cancer	2.5e-05	8.5e-05	CcSEcCtD
Citalopram—Hypertension—Doxorubicin—kidney cancer	2.49e-05	8.48e-05	CcSEcCtD
Citalopram—Chest pain—Doxorubicin—kidney cancer	2.45e-05	8.36e-05	CcSEcCtD
Citalopram—Myalgia—Doxorubicin—kidney cancer	2.45e-05	8.36e-05	CcSEcCtD
Citalopram—Arthralgia—Doxorubicin—kidney cancer	2.45e-05	8.36e-05	CcSEcCtD
Citalopram—Anxiety—Doxorubicin—kidney cancer	2.45e-05	8.33e-05	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	2.44e-05	8.3e-05	CcSEcCtD
Citalopram—Discomfort—Doxorubicin—kidney cancer	2.42e-05	8.26e-05	CcSEcCtD
Citalopram—Dizziness—Capecitabine—kidney cancer	2.41e-05	8.22e-05	CcSEcCtD
Citalopram—Dry mouth—Doxorubicin—kidney cancer	2.4e-05	8.17e-05	CcSEcCtD
Citalopram—Confusional state—Doxorubicin—kidney cancer	2.37e-05	8.08e-05	CcSEcCtD
Citalopram—Anaphylactic shock—Doxorubicin—kidney cancer	2.35e-05	8.01e-05	CcSEcCtD
Citalopram—Oedema—Doxorubicin—kidney cancer	2.35e-05	8.01e-05	CcSEcCtD
Citalopram—Infection—Doxorubicin—kidney cancer	2.34e-05	7.96e-05	CcSEcCtD
Citalopram—Vomiting—Capecitabine—kidney cancer	2.32e-05	7.9e-05	CcSEcCtD
Citalopram—Shock—Doxorubicin—kidney cancer	2.31e-05	7.88e-05	CcSEcCtD
Citalopram—Nervous system disorder—Doxorubicin—kidney cancer	2.31e-05	7.86e-05	CcSEcCtD
Citalopram—Thrombocytopenia—Doxorubicin—kidney cancer	2.3e-05	7.84e-05	CcSEcCtD
Citalopram—Rash—Capecitabine—kidney cancer	2.3e-05	7.84e-05	CcSEcCtD
Citalopram—Dermatitis—Capecitabine—kidney cancer	2.3e-05	7.83e-05	CcSEcCtD
Citalopram—Tachycardia—Doxorubicin—kidney cancer	2.3e-05	7.82e-05	CcSEcCtD
Citalopram—Headache—Capecitabine—kidney cancer	2.29e-05	7.79e-05	CcSEcCtD
Citalopram—Skin disorder—Doxorubicin—kidney cancer	2.28e-05	7.78e-05	CcSEcCtD
Citalopram—Hyperhidrosis—Doxorubicin—kidney cancer	2.27e-05	7.75e-05	CcSEcCtD
Citalopram—Anorexia—Doxorubicin—kidney cancer	2.24e-05	7.64e-05	CcSEcCtD
Citalopram—Hypotension—Doxorubicin—kidney cancer	2.2e-05	7.49e-05	CcSEcCtD
Citalopram—Nausea—Capecitabine—kidney cancer	2.17e-05	7.38e-05	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Doxorubicin—kidney cancer	2.14e-05	7.3e-05	CcSEcCtD
Citalopram—Insomnia—Doxorubicin—kidney cancer	2.13e-05	7.25e-05	CcSEcCtD
Citalopram—Paraesthesia—Doxorubicin—kidney cancer	2.11e-05	7.19e-05	CcSEcCtD
Citalopram—Dyspnoea—Doxorubicin—kidney cancer	2.1e-05	7.14e-05	CcSEcCtD
Citalopram—Somnolence—Doxorubicin—kidney cancer	2.09e-05	7.12e-05	CcSEcCtD
Citalopram—Dyspepsia—Doxorubicin—kidney cancer	2.07e-05	7.05e-05	CcSEcCtD
Citalopram—Decreased appetite—Doxorubicin—kidney cancer	2.04e-05	6.96e-05	CcSEcCtD
Citalopram—Gastrointestinal disorder—Doxorubicin—kidney cancer	2.03e-05	6.92e-05	CcSEcCtD
Citalopram—Fatigue—Doxorubicin—kidney cancer	2.03e-05	6.91e-05	CcSEcCtD
Citalopram—Constipation—Doxorubicin—kidney cancer	2.01e-05	6.85e-05	CcSEcCtD
Citalopram—Pain—Doxorubicin—kidney cancer	2.01e-05	6.85e-05	CcSEcCtD
Citalopram—Feeling abnormal—Doxorubicin—kidney cancer	1.94e-05	6.6e-05	CcSEcCtD
Citalopram—Gastrointestinal pain—Doxorubicin—kidney cancer	1.92e-05	6.55e-05	CcSEcCtD
Citalopram—Urticaria—Doxorubicin—kidney cancer	1.87e-05	6.36e-05	CcSEcCtD
Citalopram—Abdominal pain—Doxorubicin—kidney cancer	1.86e-05	6.33e-05	CcSEcCtD
Citalopram—Body temperature increased—Doxorubicin—kidney cancer	1.86e-05	6.33e-05	CcSEcCtD
Citalopram—Hypersensitivity—Doxorubicin—kidney cancer	1.73e-05	5.9e-05	CcSEcCtD
Citalopram—Asthenia—Doxorubicin—kidney cancer	1.69e-05	5.75e-05	CcSEcCtD
Citalopram—Pruritus—Doxorubicin—kidney cancer	1.66e-05	5.67e-05	CcSEcCtD
Citalopram—Diarrhoea—Doxorubicin—kidney cancer	1.61e-05	5.48e-05	CcSEcCtD
Citalopram—Dizziness—Doxorubicin—kidney cancer	1.56e-05	5.3e-05	CcSEcCtD
Citalopram—Vomiting—Doxorubicin—kidney cancer	1.5e-05	5.09e-05	CcSEcCtD
Citalopram—Rash—Doxorubicin—kidney cancer	1.48e-05	5.05e-05	CcSEcCtD
Citalopram—Dermatitis—Doxorubicin—kidney cancer	1.48e-05	5.05e-05	CcSEcCtD
Citalopram—Headache—Doxorubicin—kidney cancer	1.47e-05	5.02e-05	CcSEcCtD
Citalopram—Nausea—Doxorubicin—kidney cancer	1.4e-05	4.76e-05	CcSEcCtD
Citalopram—HRH1—Signaling by GPCR—POMC—kidney cancer	7.85e-06	0.000173	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—POMC—kidney cancer	7.83e-06	0.000172	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PGK1—kidney cancer	7.81e-06	0.000172	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC5A3—kidney cancer	7.81e-06	0.000172	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTT1—kidney cancer	7.77e-06	0.000171	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ACHE—kidney cancer	7.77e-06	0.000171	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IGF1R—kidney cancer	7.76e-06	0.00017	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—POMC—kidney cancer	7.71e-06	0.000169	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—LDHB—kidney cancer	7.66e-06	0.000168	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—SCARB1—kidney cancer	7.54e-06	0.000166	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—RAF1—kidney cancer	7.47e-06	0.000164	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS1—kidney cancer	7.46e-06	0.000164	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—IL2—kidney cancer	7.38e-06	0.000162	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—SCARB1—kidney cancer	7.35e-06	0.000162	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ACHE—kidney cancer	7.32e-06	0.000161	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTT1—kidney cancer	7.32e-06	0.000161	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CRABP1—kidney cancer	7.32e-06	0.000161	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PSMD7—kidney cancer	7.32e-06	0.000161	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSTP1—kidney cancer	7.3e-06	0.000161	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS1—kidney cancer	7.28e-06	0.00016	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSTP1—kidney cancer	7.15e-06	0.000157	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PSMD7—kidney cancer	7.14e-06	0.000157	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF2—kidney cancer	6.95e-06	0.000153	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—BCHE—kidney cancer	6.93e-06	0.000152	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—SCARB1—kidney cancer	6.93e-06	0.000152	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF2—kidney cancer	6.93e-06	0.000152	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN2B—kidney cancer	6.92e-06	0.000152	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ABCB1—kidney cancer	6.91e-06	0.000152	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN2B—kidney cancer	6.9e-06	0.000152	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS1—kidney cancer	6.86e-06	0.000151	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—SLC5A5—kidney cancer	6.85e-06	0.000151	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF2—kidney cancer	6.82e-06	0.00015	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ITPR2—kidney cancer	6.8e-06	0.00015	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN2B—kidney cancer	6.79e-06	0.000149	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ABCB1—kidney cancer	6.77e-06	0.000149	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—BCHE—kidney cancer	6.77e-06	0.000149	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PSMD7—kidney cancer	6.73e-06	0.000148	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF1R—kidney cancer	6.72e-06	0.000148	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSTM1—kidney cancer	6.71e-06	0.000148	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL2—kidney cancer	6.7e-06	0.000147	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF1R—kidney cancer	6.7e-06	0.000147	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—SLC5A5—kidney cancer	6.69e-06	0.000147	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CA9—kidney cancer	6.64e-06	0.000146	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—SLC2A1—kidney cancer	6.62e-06	0.000145	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1R—kidney cancer	6.59e-06	0.000145	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSTM1—kidney cancer	6.57e-06	0.000144	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—RAF1—kidney cancer	6.48e-06	0.000142	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—SLC2A1—kidney cancer	6.46e-06	0.000142	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—RAF1—kidney cancer	6.45e-06	0.000142	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.42e-06	0.000141	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—IL2—kidney cancer	6.39e-06	0.000141	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HIF1A—kidney cancer	6.38e-06	0.00014	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—BCHE—kidney cancer	6.38e-06	0.00014	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—IL2—kidney cancer	6.37e-06	0.00014	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TSC2—kidney cancer	6.37e-06	0.00014	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP1A1—kidney cancer	6.36e-06	0.00014	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	6.35e-06	0.00014	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—SLC5A5—kidney cancer	6.3e-06	0.000139	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	6.27e-06	0.000138	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.27e-06	0.000138	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP1A1—kidney cancer	6.23e-06	0.000137	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTT1—kidney cancer	6.2e-06	0.000136	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ACHE—kidney cancer	6.2e-06	0.000136	CbGpPWpGaD
Citalopram—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	6.16e-06	0.000135	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KDR—kidney cancer	6.11e-06	0.000134	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—SLC2A1—kidney cancer	6.08e-06	0.000134	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SCARB1—kidney cancer	5.87e-06	0.000129	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS1—kidney cancer	5.81e-06	0.000128	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL2—kidney cancer	5.81e-06	0.000128	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL2—kidney cancer	5.79e-06	0.000127	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PSMD7—kidney cancer	5.7e-06	0.000125	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL2—kidney cancer	5.7e-06	0.000125	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CRABP1—kidney cancer	5.65e-06	0.000124	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KIT—kidney cancer	5.62e-06	0.000124	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—APC—kidney cancer	5.62e-06	0.000124	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.6e-06	0.000123	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HIF1A—kidney cancer	5.53e-06	0.000122	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TSC2—kidney cancer	5.52e-06	0.000121	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTP1—kidney cancer	5.52e-06	0.000121	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HIF1A—kidney cancer	5.51e-06	0.000121	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TSC2—kidney cancer	5.5e-06	0.000121	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	5.43e-06	0.000119	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TSC2—kidney cancer	5.42e-06	0.000119	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—BCHE—kidney cancer	5.4e-06	0.000119	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—MAPK3—kidney cancer	5.39e-06	0.000118	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTP1—kidney cancer	5.39e-06	0.000118	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—POMC—kidney cancer	5.35e-06	0.000118	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SLC5A5—kidney cancer	5.34e-06	0.000117	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KDR—kidney cancer	5.29e-06	0.000116	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—BRAF—kidney cancer	5.29e-06	0.000116	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KDR—kidney cancer	5.27e-06	0.000116	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ITPR2—kidney cancer	5.25e-06	0.000115	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ABCB1—kidney cancer	5.22e-06	0.000115	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KDR—kidney cancer	5.19e-06	0.000114	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SLC2A1—kidney cancer	5.15e-06	0.000113	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—MAPK1—kidney cancer	5.13e-06	0.000113	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTP1—kidney cancer	5.08e-06	0.000112	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTM1—kidney cancer	5.07e-06	0.000111	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	5e-06	0.00011	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTM1—kidney cancer	4.95e-06	0.000109	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—kidney cancer	4.9e-06	0.000108	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APC—kidney cancer	4.87e-06	0.000107	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KIT—kidney cancer	4.87e-06	0.000107	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KIT—kidney cancer	4.86e-06	0.000107	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APC—kidney cancer	4.86e-06	0.000107	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—KRAS—kidney cancer	4.84e-06	0.000106	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP1A1—kidney cancer	4.81e-06	0.000106	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ABCB1—kidney cancer	4.8e-06	0.000106	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ACHE—kidney cancer	4.79e-06	0.000105	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTT1—kidney cancer	4.79e-06	0.000105	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KIT—kidney cancer	4.78e-06	0.000105	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APC—kidney cancer	4.78e-06	0.000105	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—POMC—kidney cancer	4.74e-06	0.000104	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP1A1—kidney cancer	4.69e-06	0.000103	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK3—kidney cancer	4.67e-06	0.000103	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTM1—kidney cancer	4.66e-06	0.000103	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK3—kidney cancer	4.65e-06	0.000102	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—POMC—kidney cancer	4.65e-06	0.000102	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—POMC—kidney cancer	4.64e-06	0.000102	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—POMC—kidney cancer	4.62e-06	0.000102	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—BRAF—kidney cancer	4.58e-06	0.000101	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	4.58e-06	0.000101	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—BRAF—kidney cancer	4.57e-06	0.0001	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—POMC—kidney cancer	4.55e-06	0.0001	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SCARB1—kidney cancer	4.53e-06	9.96e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—BRAF—kidney cancer	4.5e-06	9.88e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS1—kidney cancer	4.49e-06	9.86e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	4.45e-06	9.78e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK1—kidney cancer	4.44e-06	9.76e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK1—kidney cancer	4.43e-06	9.73e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP1A1—kidney cancer	4.42e-06	9.72e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RAF1—kidney cancer	4.41e-06	9.7e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PSMD7—kidney cancer	4.4e-06	9.67e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—RELA—kidney cancer	4.4e-06	9.66e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ERBB2—kidney cancer	4.37e-06	9.6e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.36e-06	9.59e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	4.36e-06	9.58e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MTOR—kidney cancer	4.31e-06	9.48e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTP1—kidney cancer	4.3e-06	9.45e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—kidney cancer	4.24e-06	9.33e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—kidney cancer	4.23e-06	9.3e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—KRAS—kidney cancer	4.19e-06	9.22e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—KRAS—kidney cancer	4.18e-06	9.19e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—BCHE—kidney cancer	4.17e-06	9.17e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	4.16e-06	9.16e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.12e-06	9.06e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	4.12e-06	9.05e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCB1—kidney cancer	4.07e-06	8.95e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	4.04e-06	8.89e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SLC2A1—kidney cancer	3.98e-06	8.75e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—kidney cancer	3.96e-06	8.7e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—kidney cancer	3.95e-06	8.69e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.95e-06	8.68e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—kidney cancer	3.86e-06	8.48e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—kidney cancer	3.85e-06	8.47e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—JUN—kidney cancer	3.85e-06	8.47e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—kidney cancer	3.84e-06	8.45e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RAF1—kidney cancer	3.83e-06	8.41e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	3.82e-06	8.4e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RAF1—kidney cancer	3.81e-06	8.38e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—RELA—kidney cancer	3.81e-06	8.37e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—RELA—kidney cancer	3.8e-06	8.35e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ERBB2—kidney cancer	3.78e-06	8.32e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—kidney cancer	3.78e-06	8.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	3.78e-06	8.31e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ERBB2—kidney cancer	3.77e-06	8.29e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RAF1—kidney cancer	3.75e-06	8.25e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1A1—kidney cancer	3.75e-06	8.23e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—RELA—kidney cancer	3.74e-06	8.22e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MTOR—kidney cancer	3.73e-06	8.21e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—kidney cancer	3.72e-06	8.19e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MTOR—kidney cancer	3.72e-06	8.18e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	3.71e-06	8.16e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—kidney cancer	3.71e-06	8.15e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MTOR—kidney cancer	3.66e-06	8.06e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—POMC—kidney cancer	3.58e-06	7.88e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CDKN1B—kidney cancer	3.5e-06	7.71e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—POMC—kidney cancer	3.5e-06	7.69e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CDKN1B—kidney cancer	3.49e-06	7.68e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	3.44e-06	7.56e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—kidney cancer	3.43e-06	7.54e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—kidney cancer	3.42e-06	7.52e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—kidney cancer	3.37e-06	7.4e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—kidney cancer	3.36e-06	7.4e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—kidney cancer	3.34e-06	7.35e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—JUN—kidney cancer	3.34e-06	7.33e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—kidney cancer	3.33e-06	7.33e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—JUN—kidney cancer	3.33e-06	7.31e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTP1—kidney cancer	3.32e-06	7.29e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CTNNB1—kidney cancer	3.31e-06	7.28e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CTNNB1—kidney cancer	3.3e-06	7.26e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—kidney cancer	3.3e-06	7.25e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—POMC—kidney cancer	3.3e-06	7.25e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—kidney cancer	3.28e-06	7.21e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—JUN—kidney cancer	3.27e-06	7.2e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	3.25e-06	7.14e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—kidney cancer	3.23e-06	7.1e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—kidney cancer	3.23e-06	7.09e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—kidney cancer	3.22e-06	7.07e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—kidney cancer	3.18e-06	7e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—kidney cancer	3.17e-06	6.96e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCB1—kidney cancer	3.14e-06	6.91e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MYC—kidney cancer	3.1e-06	6.8e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.08e-06	6.76e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—kidney cancer	3.05e-06	6.7e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK1—kidney cancer	3.03e-06	6.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—kidney cancer	2.91e-06	6.41e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—kidney cancer	2.91e-06	6.39e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1A1—kidney cancer	2.89e-06	6.35e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	2.86e-06	6.29e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KRAS—kidney cancer	2.86e-06	6.29e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—kidney cancer	2.86e-06	6.28e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—POMC—kidney cancer	2.79e-06	6.14e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—kidney cancer	2.79e-06	6.13e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—kidney cancer	2.76e-06	6.06e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—kidney cancer	2.75e-06	6.04e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	2.71e-06	5.95e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MYC—kidney cancer	2.68e-06	5.9e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MYC—kidney cancer	2.67e-06	5.88e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MYC—kidney cancer	2.63e-06	5.79e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—kidney cancer	2.63e-06	5.78e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	2.63e-06	5.78e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK1—kidney cancer	2.62e-06	5.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK1—kidney cancer	2.62e-06	5.75e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	2.57e-06	5.66e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—kidney cancer	2.54e-06	5.59e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—kidney cancer	2.49e-06	5.48e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KRAS—kidney cancer	2.48e-06	5.45e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KRAS—kidney cancer	2.47e-06	5.43e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—kidney cancer	2.43e-06	5.35e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KRAS—kidney cancer	2.43e-06	5.35e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—kidney cancer	2.33e-06	5.12e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—kidney cancer	2.29e-06	5.04e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—kidney cancer	2.28e-06	5.01e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—kidney cancer	2.28e-06	5.01e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—kidney cancer	2.27e-06	4.99e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	2.23e-06	4.91e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—kidney cancer	2.23e-06	4.9e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—kidney cancer	2.2e-06	4.84e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—kidney cancer	2.2e-06	4.83e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—kidney cancer	2.16e-06	4.75e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—POMC—kidney cancer	2.16e-06	4.74e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—kidney cancer	1.94e-06	4.27e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—kidney cancer	1.76e-06	3.87e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—kidney cancer	1.72e-06	3.78e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—kidney cancer	1.72e-06	3.77e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—kidney cancer	1.62e-06	3.56e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—kidney cancer	1.5e-06	3.3e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—kidney cancer	1.37e-06	3.01e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.06e-06	2.33e-05	CbGpPWpGaD
